Human CXCL4 / PF4 recombinant protein
Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form.
Platelet factor 4
Protein short names
PF4; PF-4; MGC138298; SCYB4; CXCL4
PF4; CXCL4; SCYB4
A DNA sequence encoding the human CXCL4 (NP_002610.1) (Glu 32-Ser 101) was expressed.
The recombinant human CXCL4 comprises 71 amino acids with a predicted molecular mass of 7.8 kDa as estimated in SDS-PAGE under reducing conditions.
> 80 % as determined by SDS-PAGE
1. Measured by its ability to inhibit human bFGF / FGF2 dependent proliferation of Balb/c3T3 mouse fibroblasts. The ED50 for this effect is typically 5-40 μg/ml.
2. Measured by its binding ability in a functional ELISA. Immobilized human CXCL4 at 20 μg/ml (100 μl/well) can bind biotinylated human VEGF165. The EC50 of biotinylated human VEGF165 is 9.97 μg/ml.
Human CXCL4 / PF4 Protein SDS-PAGE
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"